Application of radiomics in evaluating tumor immune cell infiltration and predicting response to anti‐PD‐1 therapy has been promising: a radiomic signature that measures the intensity of tumor‐infiltrating CD8 cells was identified. The gene discussed is CD8A; the disease is neoplasm.